Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

[Concentration of serum soluble forms of ICAM-1 (sVCAM-1) and VCAM-1 (sVCAM-1) in patients with chronic pancreatitis and in patients with pancreatic carcinoma]

Authors: Markocka-Maczka, K 
Citation: Markocka-Maczka K Wiad Lek. 2003;56(3-4):147-51.
Pubmed: (View Article at PubMed) PMID:12923961

Cellular adhesion plays a major role in many biological processes--in cells' growth, their differentiation, migration and apoptosis. The aim of the paper is to evaluate the expression of two selected adhesion molecules at the Ig superfamily in their soluble forms (sICAM-1 and sVCAM-1) in patients with chronic pancreatitis and in patients with pancreatic carcinoma in comparison with a group of healthy people. Examinations were carried out on healthy people (n = 32), patients with chronic pancreatitis (n = 32) and with pancreatic cancer (n = 32). The selected adhesion molecules concentrations were assessed using immunoassay of solid phase (ELISA). RESULTS: sICAM-1 and sVCAM-1 values in the sera of patients with chronic pancreatitis and with pancreatic carcinoma were significantly higher (p < 0.01) in comparison with the results obtained in the control group. In the group of patients with chronic pancreatitis the results were significantly lower in comparison with concentration in the group of patients with pancreatic carcinoma (p < 0.05, p < 0.01). sICAM-1 and sVCAM-1 values in patients with remote metastases were higher than in patients without metastases (p < 0.01). CONCLUSIONS: Overexpression of sICAM-1 and sVCAM-1 is characteristic for chronic pancreatitis and pancreatic cancer. Values of sICAM-1 and sVCAM-1 concentrations in serum of patients with pancreatic cancer demonstrate connection with a state of clinical progression of tumour.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 2325163
Created: 2010-05-21
Species: All species
Last Modified: 2010-05-21
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.